Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Clinical trial NCT07526493 · RECRUITING

Trial details

NCT number: NCT07526493
Sponsor: Tongji Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)Autoimmune Encephalitis (AE)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Myasthenia Gravis (MG)Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD)Idiopathic Inflammatory Myopathies (IIM)

Start date: 2026-04-01
Primary completion: 2027-12-31
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.